Issue	Blueprint Recommendations	Party	Action Steps	Milestones
Increase Competition	**Encourage the development of more generic prescription drugs to help lower overall costs.** FDA will issue guidance to address how manufacturers may seek to use shared system REMS to delay or block competition from generic products entering the market.		HHS solicited comments on how REMS programs could be modified to prevent restrictions on drug distribution that may be affecting the development of generic drugs.	+ Released 5/16/18 + Comments due 7/16/18
			S.3792 would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market and biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.	+ Introduced 12/19/2018 + Referred to Judiciary Cmte. 12/19/18 + Needs to be reintroduced
	Promote innovation and competition for biologics. FDA will issue policies to improve availability, competitiveness and adoption of biosimilars as affordable alternatives to branded biologics. FDA will continue to educate clinicians, patients and payers about biosimilar and interchangeable products, seeking to increase awareness about these important new treatments.		HHS solicited comments on how the FDA could improve provider education regarding the use of biosimilars and whether policy changes could improve the interchangeability of biosimilars.	+ Released 5/16/18 + Comments due 7/16/18
			FDA recently unveiled an 11-part action plan to encourage innovation and competition among biologics and the development of biosimilars.	+ Released July 2018